Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 2, 1999, Pages 459-466

  Takehana, Yasuo ^a,b   Kurokawa, Toru ^b   Kitamura, Tsuyoshi ^a   Tsukahara, Yoshimi ^a   Akahane, Satoshi ^a   Kitazawa, Makio ^a   Yoshimura, Nagahisa ^b  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; TRANILAST;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIODE LASER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; LASER COAGULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTHRANILIC ACIDS; ANTI-ALLERGIC AGENTS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; INDOMETHACIN; LASER COAGULATION; RATS; RATS, INBRED BN;

EID: 0032947764     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hyman LG, Lilienfeld AM, Ferris FL III, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118: 215-227.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
3. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988;128:700-710.
4. The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
5. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992; 99:933-943.
6. Sarks SH. New vessel formation beneath the retinal pigment epithelium in senile eyes. Br J Ophthalmol. 1973;57:951-965.
7. Green WR, Key SN III. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc. 1977;75:180-254.
8. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularization. Ophthalmology. 1992;99:952-968.
9. Bressler NM. Submacular surgery: are randomized trials necessary? Arch Ophthalmol. 1995;113:1557-1560.
10. Bressler NM. Submacular surgery: new information, more questions. Arch Ophthalmol. 1997;115:1071-1072.
11. Kaplan H. Submacular surgery for choroidal neovascularization. Br J Ophthalmol. 1996;80:101.
12. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109: 1220-1231.
13. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503-512.
14. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol. 1989; 107:344-352.
15. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990;108:825-831.
16. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980;208:516-518.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
18. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol. 1997;115:865-872.
19. Ip M, Gorin MB. Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol. 1996;122:594-595.
20. Koda A, Nagai H, Watanabe S, Yanagihara Y, Sakamoto K. Inhibition of hypersensitivity reactions by a new drug, N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′). J Allergy Clin Immunol. 1976;57:396-407.
21. Komatsu H, Kojima M, Tsutsumi N, et al. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol. 1988;46:43-51.
22. Isaji M, Aruga N, Naito J, Miyata H. Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro. Life Sci. 1994;55:PL287-PL292.
23. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992;60:91-96.
24. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 1992;60:85-90.
25. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107:179-185.
26. Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol. 1997;122:1061-1066.
27. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol. 1989; 107:267-269.
28. Ryan SJ. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc. 1979;77:707-745.
29. Archer DB, Gardiner TA. Experimental subretinal neovascularization. Trans Ophthalmol Soc UK. 1980;100:363-368.
30. Van der Zypen E, Fankhauser F, Raess K. Choroidal reaction and vascular repair after chorioretinal photocoagulation with the free-running neodymium-YAG laser. Arch Ophthalmol. 1985;103:580-589.
31. Van der Zypen E, Fankhauser F, Raess K, England C. Morphologic findings in the rabbit retina following irradiation with the free-running neodymium-YAG laser: disruption of Bruch's membrane and its effect on the scarring process in the retina and choroid. Arch Ophthalmol. 1986;104:1070-1077.
32. Perry DD, Risco JM. Choroidal microvascular repair after argon laser photocoagulation. Am J Ophthalmol. 1982;93:787-793.
33. Perry DD, Reddick RL, Risco JM. Choroidal microvascular repair after argon laser photocoagulation: ultrastructural observations. Invest Ophthalmol Vis Sci. 1984;25:1019-1026.
34. Pollack A, Heriot WJ, Henkind P. Cellular processes causing detects in Bruch's membrane following krypton laser photocoagulation. Ophthalmology. 1986;93:1113-1119.
35. Pollack A, Korte GE, Weitzner AL, Henkind P. Ultrastructure of Bruch's membrane after krypton laser photocoagulation, I: breakdown of Bruch's membrane. Arch Ophthalmol. 1986;104:1372-1376.
36. Pollack A, Korte GE, Heriot WJ, Henkind P. Ultrastructure of Bruch's membrane after krypton laser photocoagulation, II: repair of Bruch's membrane and the role of macrophages. Arch Ophthalmol. 1986;104:1377-1382.
37. Baurmann H, Sasaki K, Chioralia G. Investigations on laser coagulated rat eyes by fluorescence angiography and microscopy. Graefes Arch Clin Exp Ophthalmol. 1975;193:245-252.
38. Frank RN, Das A, Weber ML. A model of subretinal neovascularization in the pigmented rat. Curr Eye Res. 1989;8:239-247.
39. Mainster MA. Wavelength selection in macular photocoagulation: tissue optics, thermal effects, and laser systems. Ophthalmology. 1986;93:952-958.
40. Kosuga K, Tamai H, Ueda K, et al. Effectiveness of tranilast on restenosis after directional coronary atherectomy. Am Heart J. 1997;134:712-718.
41. Thomas A, Deutsch AB, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-540.
42. Harvey PT, Cherry PMH. Indomethacin v. dexamethasone in the suppression of corneal neovascularization. Can J Ophthalmol. 1983;18:293-295.
43. Frucht J, Zauberman H. Topical indomethacin effect on neovascularization of the cornea and on prostaglandin E2 levels. Br J Ophthalmol. 1984;68:656-659.
44. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593.
45. Sakamoto T, Soriano D, Nassaralla J, et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1995; 113:222-226.
46. Komatsu H, Kojima M, Tsutsumi N, et al. Mechanism of inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: effect of tranilast on the release of arachidonic acid and its metabolites. Jpn J Pharmacol. 1988;46: 53-60.
47. Tamai H, Katou K, Hayakawa H, et al. The impact of tranilast on restenosis following coronary angioplasty: the second tranilast restenosis following angioplasty trial (TREAT-2) (Abstract). Circulation. 1996;94(suppl I):I-620.